Cabotegravir-LA Safe in Women, Challenges Remain

11:05 EDT 28 Jul 2017 | Medscape

Long-acting cabotegravir with an 8-week dosing schedule is effective for the prevention of HIV in men and women, new research shows, but will it be embraced by people looking for long-term protection?
Medscape Medical News

Original Article: Cabotegravir-LA Safe in Women, Challenges Remain


More From BioPortfolio on "Cabotegravir-LA Safe in Women, Challenges Remain"

Quick Search

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...